Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Alpelisib has demonstrated a unique efficacy against PIK3CA mutations in HR/HER2- advanced breast cancer, and the combination with fulvestrant further enhances the anti-tumor effec···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：462
Patients with HR/HER2- advanced breast cancer harboring PIK3CA mutations were significantly delayed in disease progression under the combination of Alpelisib and fulvestrant.What i···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：619
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic strategy for patients with HR/HER2- advanced breast cancer.What diseases can be treated with Alpeli···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：557
Alpelisib fills a gap in the treatment of HR/HER2- breast cancer, particularly in patients with PIK3CA mutations, and the combination of fulvestrant improves efficacy.Who is Alpeli···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：517
For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib and fulvestrant is a precision treatment for PIK3CA mutations.Who is Alpelisib for?Alpelisib is suit···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：497
As a PIK3CA inhibitor, Alpelisib works synergistically with fulvestrant to significantly improve the prognosis of breast cancer patients with HR/HER2- and PIK3CA mutations.What is ···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：650
Alpelisib effectively inhibits the proliferation of HR/HER2- breast cancer cells by inhibiting the PI3K pathway, which is especially suitable for advanced cases with PIK3CA mutatio···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：604
The combination of Alpelisib and fulvestrant specifically targeted patients with advanced breast cancer with HR/HER2- and PIK3CA mutations significantly prolongs progression-free s···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：510
Koselugois a multifunctional targeted therapy drug, which can be used as a small molecule MEK inhibitor for the treatment of low-grade serous ovarian cancer, etc., and as a tyrosin···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：512
Koselugo is a targeted therapy that targets specific cancers by inhibiting the activity of key enzymes to block the growth of cancer cells.Which drugs interact with KoselugoThere a···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：526
Koselugo is a targeted therapy drug for the treatment of low-grade serous ovarian cancer, neurofibromas, etc., by inhibiting MEK protein kinase and RET tyrosine kinase activity.Wha···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：529
Koselugois an anti-cancer drug targeting MEK protein, which can successfully block cell signaling pathways and inhibit the proliferation of tumor cells, with significant and superi···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：510
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：8532025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：10502024-09-07
Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding cou···【more】
Recommended：3112026-10-10
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended：4052026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended：5982026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended：5702026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended：4562026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended：6072026-31-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
